Tier 4 — mechanistic

An Open-Label Intervention Trial to Reduce Senescence and Improve Frailty in Adult Survivors of Childhood Cancer (SEN-SURVIVORS)

Gregory T. Armstrong
ClinicalTrials.gov trial registry record 2021

Bibliography

Trial registry
View on ClinicalTrials.gov Registered trial — results not yet published in a peer-reviewed journal.
Funding
Sponsor: St. Jude Children's Research Hospital / National Cancer Institute-supported program.
Competing interests
Not reported in the registry record.

Study snapshot

DesignOpen-label randomized active-comparator Phase 2 trial comparing fisetin with dasatinib plus quercetin.
ModelAdult survivors of childhood cancer with frailty/senescence outcomes.
SampleCurrent 2026 sources report planned enrollment up to 110 participants; earlier registry summaries listed smaller targets as the protocol evolved.
InterventionFisetin 20 mg/kg/day on Days 1, 2, 30 and 31, compared with dasatinib plus quercetin on a separate active-treatment schedule.
DurationTreatment through Day 31 with primary follow-up around Day 60 and extended follow-up around Day 150.
EndpointsWalking speed; Blood p16INK4a senescence marker; Frailty measures; Inflammation; Insulin resistance; Bone resorption; Cognitive function; Safety and tolerability

What the study showed, in plain terms

SEN-SURVIVORS tests two senolytic strategies in adult survivors of childhood cancer: fisetin alone versus dasatinib plus quercetin. It measures walking speed and blood-cell senescence markers, with additional frailty and safety outcomes.

The trial is active but not recruiting and has no posted outcome results. Because there is no untreated or placebo arm, future changes will need to be interpreted as a comparison between two active senolytic strategies rather than against no treatment.

Key findings

  • The fisetin arm uses 20 mg/kg/day on Days 1, 2, 30 and 31.
  • The comparator is dasatinib plus quercetin, not placebo.
  • Primary outcomes include walking speed and p16INK4a-positive blood cells.

What this study can and cannot tell us

  • No results posted yet.
  • Open-label active-comparator design does not include a placebo/no-treatment arm.
  • Cancer-survivor population limits generalizability to general longevity supplementation.

Citation network

Articles citing this research paper

2 articles

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology